CA: A Cancer Journal for Clinicians, 1993 The etiology of Hodgkin's disease is unknown, and the identity of the normal counterpart of the malignant cell involved in Hodgkin's disease remains controversial. Yet, three of every four patients diagnosed with Hodgkin's disease will be cured. This success in treatment is due in large part to the application of modern oncologic techniques, such as ...
E L, Weinshel, B A, Peterson
exaly +8 more sources
Serum biomarkers and clinical characteristics of patients with Hodgkin lymphoma [PDF]
Vojnosanitetski Pregled, 2018 Background/Aim. In classical Hodgkin’s lymphoma (cHL) the existing prognostic scoring systems do not include markers that adequately reflect the interaction of malignant Hodgkin and Reed-Sternberg (HRS) cells and tumor environment.
Simonović Olivera +6 more
doaj +1 more source
Composite follicular lymphoma and classic Hodgkin lymphoma [PDF]
Journal of Pathology and Translational Medicine, 2022 Composite lymphoma is very rare and a combination of Hodgkin lymphoma and non-Hodgkin lymphoma and even histiocytic tumors can occur. Because of the unfamiliarity, not only can this cause diagnostic problems, but can also affect treatment plan. We report
Han-Na Kim +5 more
doaj +1 more source
Human Vaccines & Immunotherapeutics, 2023 Individuals who are immunocompromised (IC) due to therapy or underlying disease are at increased risk of herpes zoster (HZ). This study evaluates the public health impact of recombinant zoster vaccine (RZV) relative to no HZ vaccination for the ...
Desmond Curran +8 more
doaj +1 more source
Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year followup in the West of Scotland Cancer Network [PDF]
, 2011 Clinically and biologically, nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) has much more in common with germinal-center derived B-cell non-Hodgkin lymphoma (NHL) than with classical Hodgkin lymphoma (cHL).
Diehl V +8 more
core +1 more source
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. [PDF]
, 2016 Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase II ...
Falchook, Gerald S. +17 more
core +2 more sources
Vitamin D3 receptor is highly expressed in Hodgkin's lymphoma [PDF]
, 2012 Background: Hodkin s lymphoma is one of the most frequent lymphoma in western world. Despite an overall good prognosis some patients suffer relapsing tumors which are difficult to cure.
Benz, Alexander +2 more
core +2 more sources
Human leukocyte antigens and genetic susceptibility to lymphoma [PDF]
, 2015 Familial aggregation, coupled with ethnic variation in incidence, suggests that inherited susceptibility plays a role in the development of lymphoma, and the search for genetic risk factors has highlighted the contribution of the human leukocyte antigen (
Jarrett, R.F., McAulay, K.A.
core +1 more source
Genomic analyses of microdissected Hodgkin and Reed-Sternberg cells: mutations in epigenetic regulators and p53 are frequent in refractory classic Hodgkin lymphoma [PDF]
, 2019 This work was supported by grants from the Plan Nacional de I + D + I cofinanced by the ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER), PI12/1832, the Spanish Association for Cancer Research (AECC), and ...
Astudillo, Aurora +11 more
core +2 more sources
Lymphohaematopoietic malignancies in Scottish military veterans: Retrospective cohort study of 57,000 veterans and 173,000 non-veterans [PDF]
, 2017 Background: Lymphohaematopoietic malignancies are common in the general population. There have been concerns that military service may be associated with increased risk as a result of occupational exposures.
Bergman, Beverly P. +2 more
core +1 more source